{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:05:45Z","timestamp":1794279945207,"version":"4.9.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.dsx.2023.102711","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T21:00:10Z","timestamp":1675458010000},"page":"102711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The efficacy of intranasal oxytocin in patients with Prader-Willi syndrome: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9231-7213","authenticated-orcid":false,"given":"Noran M.","family":"Shalma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa A.","family":"Alsharabasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira M.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Alsawareah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emery","family":"Manirambona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirwan K.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouran A.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abd-ElGawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2023.102711_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3345\/kjp.2011.54.2.55","article-title":"Systematic review of the clinical and genetic aspects of Prader-Willi syndrome","author":"Jin","year":"2011","journal-title":"Korean J Pediatr"},{"issue":"9","key":"10.1016\/j.dsx.2023.102711_bib2","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3390\/nu14091950","article-title":"Prader-willi syndrome: possibilities of weight gain prevention and treatment","volume":"14","author":"\u00c9","year":"2022","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.dsx.2023.102711_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000313377","article-title":"Endocrine disorders in children with Prader-Willi syndrome--data from 142 children of the French database","volume":"74","author":"Diene","year":"2010","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"10.1016\/j.dsx.2023.102711_bib4","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ajmg.a.33951","article-title":"Nutritional phases in Prader-Willi syndrome","volume":"155a","author":"Miller","year":"2011","journal-title":"Am J Med Genet"},{"issue":"6","key":"10.1016\/j.dsx.2023.102711_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/gim.2016.178","article-title":"Causes of death in prader-Willi syndrome: prader-Willi syndrome association (USA) 40-year mortality survey","volume":"19","author":"Butler","year":"2017","journal-title":"Genet Med : off j Am Coll Med Genet"},{"issue":"19","key":"10.1016\/j.dsx.2023.102711_bib6","first-page":"4540","article-title":"Anti-obesity medication use in children and adolescents with prader-Willi syndrome: case review and literature search","volume":"10","author":"Goldman","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.dsx.2023.102711_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/obr.12992","article-title":"Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: a narrative review","volume":"21","author":"Tan","year":"2020","journal-title":"Obes Rev : off j Int Assoc Stud Obesity"},{"key":"10.1016\/j.dsx.2023.102711_bib8","doi-asserted-by":"crossref","unstructured":"Burnett LC. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome2017.","DOI":"10.1172\/JCI88648"},{"key":"10.1016\/j.dsx.2023.102711_bib9","series-title":"Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases","author":"Swaab","year":"1995"},{"key":"10.1016\/j.dsx.2023.102711_bib10","series-title":"Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients","first-page":"1","author":"Tauber","year":"2011"},{"key":"10.1016\/j.dsx.2023.102711_bib11","series-title":"A\u00a0double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome","first-page":"2232","author":"Einfeld","year":"2014"},{"key":"10.1016\/j.dsx.2023.102711_bib12","series-title":"Oxytocin treatment in children with Prader\u2013Willi syndrome: a double-blind, placebo-controlled, crossover study","first-page":"1243","author":"Miller","year":"2017"},{"key":"10.1016\/j.dsx.2023.102711_bib13","series-title":"Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: a randomized controlled pilot trial","first-page":"643","author":"Hollander","year":"2021"},{"issue":"4","key":"10.1016\/j.dsx.2023.102711_bib14","first-page":"264","article-title":"Preferred reporting items for systematic reviews and meta-analyses","volume":"151","author":"Moher","year":"2009","journal-title":"the PRISMA statement"},{"key":"10.1016\/j.dsx.2023.102711_bib15","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1. 0 (updated March 2011)","article-title":"Reviews in health promotion and public health","author":"Armstrong","year":"2011"},{"key":"10.1016\/j.dsx.2023.102711_bib16","series-title":"Oxytocin in young children with Prader-Willi syndrome: results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin","first-page":"774","author":"Damen","year":"2021"},{"key":"10.1016\/j.dsx.2023.102711_bib17","series-title":"Promising effects of oxytocin on social and food-related behaviour in young children with Prader\u2013Willi syndrome: a randomized, double-blind, controlled crossover trial","first-page":"979","author":"Kuppens","year":"2016"},{"issue":"3","key":"10.1016\/j.dsx.2023.102711_bib18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12020-015-0614-x","article-title":"Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome","volume":"50","author":"Kuppens","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.dsx.2023.102711_bib19","series-title":"Phase 3 study of intranasal carbetocin (LV-101) in patients with Prader-Willi syndrome","author":"Levo Therapeutics","year":"2020"},{"issue":"Supplement_1","key":"10.1016\/j.dsx.2023.102711_bib20","doi-asserted-by":"crossref","first-page":"A689","DOI":"10.1210\/jendso\/bvab048.1403","article-title":"Topline results of the CARE-PWS phase 3 study: intranasal carbetocin improves hyperphagia and anxiety and distress symptoms in prader-Willi syndrome (PWS)","volume":"5","author":"Ryman","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"12","key":"10.1016\/j.dsx.2023.102711_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98333","article-title":"Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome","volume":"3","author":"Dykens","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.dsx.2023.102711_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41582-021-00602-9","article-title":"Refining oxytocin therapy for autism: context is key","volume":"18","author":"Ford","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.dsx.2023.102711_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41398-022-02054-1","article-title":"Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies","volume":"12","author":"Althammer","year":"2022","journal-title":"Transl Psychiatry"},{"issue":"3","key":"10.1016\/j.dsx.2023.102711_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/pcn.12627","article-title":"Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder","volume":"72","author":"Cai","year":"2018","journal-title":"Psychiatr Clin Neurosci"},{"issue":"1","key":"10.1016\/j.dsx.2023.102711_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104379","article-title":"The consequences of hyperphagia in people with Prader-Willi Syndrome: a systematic review of studies of morbidity and mortality","volume":"65","author":"Bellis","year":"2022","journal-title":"Eur J Med Genet"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:21:17Z","timestamp":1761729677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402123000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1871402123000073"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102711","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of intranasal oxytocin in patients with Prader-Willi syndrome: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102711"}}